Concert Pharmaceuticals was selected for one of two presentations focused on alopecia areata during the late-breaking research program at the American Academy of Dermatology’s annual meeting on Saturday, March 2, 2019. The presentation focused on an interim analysis from an ongoing Phase 2 clinical trial of CTP-543. CTP-543 is an investigational treatment being developed for alopecia areata.
“We are very pleased that we were selected to present our initial safety and efficacy data with CTP-543 in patients with moderate-to-severe alopecia areata to the members of the Academy,” stated Dr. James V. Cassella, Concert’s Chief Development Officer who made the oral presentation at AAD. “We look forward to advancing the development of CTP-543, as we continue our efforts to bring a new treatment to patients with this autoimmune disease that currently has no approved medications.”
The American Academy of Dermatology was founded in 1938. It is the largest, most influential and representative dermatology group in the United States. With a membership of more than 20,000, it represents virtually all practicing dermatologists in the United States, as well as a growing number of international dermatologists.